Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6-11 Years: Actual Observations and Clinical Perspectives
Arch Bronconeumol. 2025 Mar 1:S0300-2896(25)00071-7. doi: 10.1016/j.arbres.2025.02.010. Online ahead of print. ABSTRACT BACKGROUND: Cystic fibrosis causes exercise limitation due to impaired lung function and other …